TAVI in intermediate-risk patients - What should we be doing now?

Chairperson: M. Haude
Co-chairperson: N. Moat
Evaluator: H. Moellmann
Control Desk: M.Z. Khawaja


Consult this session video from EuroPCR 2015 on TAVI in intermediate-risk patients: what should we be doing now?

Learning Objectives

  • To learn how to define intermediate-risk in TAVI patients
  • To review the available evidence
  • To understand the current limitations of TAVI in this patient group

Presentations available when logged in:

  • Session objectives
  • What does intermediate-risk mean?
  • What is happening today in the real world?
  • The remaining pitfalls of TAVI